EuropaBio’s Most Innovative Biotechs 2014
EuropaBio, the European Association for Bioindustries, has announced its “top five biotech SMEs in Europe”.
EuropaBio, the European Association for Bioindustries, has announced its “top five biotech SMEs in Europe”. The companies will compete to win the 5th annual Most Innovative EU Biotech SME Award, to be awarded during European Biotech Week (October 8) in Brussels, Belgium.
Shortlisted are:
Autifony (London, UK): A healthcare biotech based at Imperial College London, focused on the development of high value novel medicines to treat hearing disorders and serious disorders of the central nervous system, such as schizophrenia.
Bio-on (Bologna, Italy): Bio-on works in industrial biotechnology applied to widely used materials, creating natural products and solutions based on renewable resources or on agricultural processing waste material.
Biosyntia (Horshølm, Denmark): An industrial biotech SME, providing unique fermentation solutions to chemical manufacturing companies.
Erytech Pharma (Lyon, France): A biopharmaceutical company developing an innovative concept to starve cancer cells in specific essential nutrients, and quickly induce their death without impairing any healthy cells.
to-BBB (Leiden, The Netherlanda): A biotech developing novel treatments for patients with devastating brain diseases. Its lead clinical programs target multiple types of brain cancers, including brain metastases from breast cancer, as well as neuro-inflammatory diseases.
This year’s award ceremony reportedly has a focus on financing, with the European Investment Bank presenting its Growth Financing Facility for funding innovative companies in the EU, and the European Commission illustrating its SME Instrument under Horizon 2020.
Click here for further information.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Merck’s Oral TLR7/8 Inhibitor Reduces Disease Activity in Cutaneous, Systemic Lupus
May 21st 2025Results from the Phase II WILLOW trial show that enpatoran achieved a statistically significant dose-response and clinically meaningful reduction in disease activity in cutaneous and systemic lupus erythematosus with active rash.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
